U.S. pharma big copyright scrapped two experimental weight loss tablets previous yr—a the moment-each day tablet, lotiglipron, because of elevated liver enzymes as well as a two times-day by day tablet, danuglipron, resulting from sturdy side effects—but CEO Albert Bourla has explain